Myeloproliferative disorders : current perspectives on diagnostic criteria, histopathology and treatment in essential thrombocythemia, polycythemia rubra vera and chronic idiopathic myelofibrosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISBN
-
9783980807562
3980807568
- Maße
-
25 cm, 448 gr.
- Umfang
-
VIII, 112 S.
- Sprache
-
Englisch
- Anmerkungen
-
Ill., graph. Darst.
Literaturverz. S. 85 - 106
- Klassifikation
-
Medizin, Gesundheit
- Schlagwort
-
Myeloproliferatives Syndrom
- Ereignis
-
Veröffentlichung
- (wo)
-
Much
- (wer)
-
Verl. ME
- (wann)
-
2005
- Urheber
-
Michiels, Jan Jacques
Kvasnicka, Hans Michael
Thiele, Jürgen
- Inhaltsverzeichnis
- Rechteinformation
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Letzte Aktualisierung
-
11.06.2025, 13:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Michiels, Jan Jacques
- Kvasnicka, Hans Michael
- Thiele, Jürgen
- Verl. ME
Entstanden
- 2005
Ähnliche Objekte (12)
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
Myelofibrosis
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors
Myelofibrosis
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
Severe delayed postpolypectomy bleeding in elder patient with post-polycythemia myelofibrosis
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors